Descartes-08, Cartesian’s lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). In January 2025 ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...

The world is digital, but sometimes the power of analog is just what is needed. The analog multiplier is a case in point with ...

Telecommunications network provider, CityFibre, is acquiring Hull-based Connexin’s full fibre infrastructure. This deal is ...

Network operator CityFibre has this morning announced their second recent acquisition of an alternative UK broadband provider ...

The S&P 500 Index ($SPX) (SPY) today is up +0,47%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.71% ...

Aerotech will be showcasing its high-precision solutions for analysing surfaces, high-performance motion control and ...

FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

CBSE Class 12 Informatics Practices Exam 2025 is tomorrow! Check out the Top 30 MCQs with answers for last-minute revision.

Opinions expressed are those of the author. Product marketing continues to emerge as a critical function in many organizations, gaining a reputation distinct from traditional marketing in growing ...